National Health Service

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Retrieved on: 
Friday, July 14, 2023

Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023.

Key Points: 
  • Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023.
  • Signed a preliminary agreement with Eversana to support a planned commercial launch of its Diabetes and Metabolic Health programs in the USA.
  • Announced initial patient data from UK NHS (National Health Service) Miboko Study that thus far demonstrated weight loss in 100% of participants, with further studies ongoing.
  • General and administrative expenses were $6,590,227 and $6,173,049 for the fiscal years ended March 31, 2023 and 2022, respectively.

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

iWantGreatCare and Top Doctors merge to become the leading company for patient reviews in the healthcare sector

Retrieved on: 
Friday, July 7, 2023

Alberto E. Porciani, CEO and Co-founder of Top Doctors, affirms the merger will bolster their technology offerings, delivering an inclusive service for medical professionals, centres, hospitals, and patients.

Key Points: 
  • Alberto E. Porciani, CEO and Co-founder of Top Doctors, affirms the merger will bolster their technology offerings, delivering an inclusive service for medical professionals, centres, hospitals, and patients.
  • IWGC's review system, he says, integrates seamlessly with PHIN (Private Healthcare Information Network) and the NHS (National Health Service).
  • The merger is hailed as a breakthrough for UK patients, providers, and clinicians by Jon Twinn, CEO of IWGC.
  • IWGC has championed transparency in healthcare through patient reviews in the UK for 15 years, publishing over 6 million reviews.

Holmusk and Streamline Healthcare Solutions Announce Strategic Partnership To Bring Behavioral Health Predictive Analytics Tool to US Market

Retrieved on: 
Thursday, June 22, 2023

NEW YORK, June 22, 2023 /PRNewswire/ -- Holmusk, a leading global behavioral health real-world evidence company, announced today that it is joining forces with one of its strategic partners, Streamline Healthcare Solutions, to enhance care delivery using advanced analytics. The partnership marks the introduction of Holmusk's Management and Supervision Tool (MaST), which is widely used by the National Health Service in the United Kingdom, to a U.S. market.

Key Points: 
  • The partnership marks the introduction of Holmusk's Management and Supervision Tool (MaST), which is widely used by the National Health Service in the United Kingdom, to a U.S. market.
  • MaST is a software platform that uses predictive analytics to help healthcare professionals make decisions, including prioritizing individuals at risk of a mental health crisis.
  • MaST's entry to the U.S. will kick off within Mental Health Partners , a network of behavioral health clinics serving communities across central Colorado.
  • Mental Health Partners already uses Streamline's SmartCareTM Behavioral Health EHR platform, and will be onboarded to using MaST to immediately benefit from data insights provided by the tool.

Electronic Health Records Market size to grow by USD 32.27 billion from 2022 to 2027; The growing use of connected devices and technologies to be a major market trend - Technavio

Retrieved on: 
Thursday, June 22, 2023

NEW YORK, June 22, 2023 /PRNewswire/ -- The electronic health records market size is set to grow by USD 32.27 billion between 2022 and 2027.

Key Points: 
  • NEW YORK, June 22, 2023 /PRNewswire/ -- The electronic health records market size is set to grow by USD 32.27 billion between 2022 and 2027.
  • Vendor Landscape - The global electronic health records market is fragmented, with the presence of several global as well as regional vendors.
  • Allscripts Healthcare Solutions Inc. - The company offers electronic health records for various purposes, ranging from independent medical professionals to large administrative health records in hospitals.
  • The health intelligent virtual assistant (IVA) market size is estimated to grow at a CAGR of 39.76% between 2022 and 2027.

It’s 4 years since the NZ government pledged $1.9 billion for better mental health services – why are we still waiting?

Retrieved on: 
Wednesday, June 21, 2023

In 2019 the New Zealand government committed an unprecedented NZ$1.9 billion to improving mental health services.

Key Points: 
  • In 2019 the New Zealand government committed an unprecedented NZ$1.9 billion to improving mental health services.
  • This announcement brought hope to a sector that had been treated like the second-class citizen of the health service for decades.

Where did the money go?

    • Almost a quarter of the funding has gone to health improvement practitioners (HIPs) and health coaches based within general medical practices.
    • The aim of these practitioners and coaches is to give fast and early access to people presenting to their general practitioner (GP) with mental health concerns.

Robbing Peter to pay Paul

    • This investment approach by the government has several problems, which mean the country’s collective mental health needs have not been successfully addressed.
    • Many nurses and psychologists have taken up practitioner roles, meaning we have robbed Peter to pay Paul as clinicians move from one area of the mental health sector to another.
    • For example, there is a growing body of local and international research highlighting the relationship of micronutrients and what we eat to our mental health.

Going global for ideas

    • Unsurprisingly, Aotearoa New Zealand is not the only country to be grappling with high demand for mental health services.
    • We can learn from what other countries are doing in response to gaps in their services.
    • The United Kingdom, for example, has attempted to address its own mental health services shortfall with a programme called Increasing Access to Psychological Therapies (IAPT).

Real action is long overdue

    • The government’s singular focus on one or two new mental health initiatives has been at the expense of training programmes.
    • To give the government its due, there has been some recent investment in clinical psychology training but it feels like an afterthought.
    • Nonetheless, looking at our mental health system in 2023 it feels like very little progress has been made.

The Lancet Oncology Publishes Results from SYMPLIFY, The First Prospective Study of a Multi-Cancer Early Detection Test in a Symptomatic Patient Population

Retrieved on: 
Tuesday, June 20, 2023

“For the majority of cancers, there are no organized screening programs and most patients diagnosed with cancer first attend primary care with symptoms.

Key Points: 
  • “For the majority of cancers, there are no organized screening programs and most patients diagnosed with cancer first attend primary care with symptoms.
  • “In the SYMPLIFY study, a significant minority of cancers were diagnosed in organs that were different from those originally suspected, given the symptoms experienced.
  • It is also encouraging to see the performance of the test in esophagus, stomach, liver, pancreas and bile duct cancers.
  • We look forward to using these results to further improve test performance in this patient population.”
    The University of Oxford sponsored the SYMPLIFY study and was responsible for data collection, analysis and interpretation.

Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom

Retrieved on: 
Tuesday, June 20, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230620673527/en/
    Omnipod® 5 Automated Insulin Delivery System (Photo: Business Wire)
    “Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” said Jim Hollingshead, Insulet President and CEO.
  • Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help protect against high and low glucose levels1.
  • The system is interoperable with the Dexcom G6 CGM for automated insulin delivery.
  • The system then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.

Bionano Announces Peer-Reviewed Publication on the Utility of Combining OGM and a 523-gene NGS Panel for Standard Evaluation of Myeloid Cancers

Retrieved on: 
Tuesday, June 20, 2023

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.

Key Points: 
  • SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.
  • The study describes myeloid cancers as posing a significant challenge to manage, with approximately 50% of cases displaying cytogenetically normal genomes, which can confound traditional analysis approaches.
  • In this blinded retrospective analysis of samples from 30 myeloid cancer subjects, the combination of OGM with the 523-gene NGS panel was compared to the common approach of KT and FISH combined with a 54-gene NGS panel.
  • A pre-commercial version of Bionano’s new NxClinical™ software enabled analysis of OGM and NGS data together, providing an integrated picture of genomic variation.